DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Alzheimer's Disease
Interventions
DRUG

DHA (Docosahexaenoic Acid)

950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months

DRUG

Placebo

2 placebo capsules twice a day for 18 months

Trial Locations (51)

10016

New York University Medical Center, New York

10032

Columbia University, New York

10468

Mount Sinai School of Medicine, The Bronx

12208

Albany Medical College, Albany

14226

Dent Neurological Institute, Amherst

14620

University of Rochester Medical Center, Rochester

15213

University of Pittsburgh, Pittsburgh

20057

Georgetown University Medical Center, Dept. of Neurology, Washington D.C.

20060

Howard University College of Medicine, Washington D.C.

20205

Johns Hopkins University Division of Cognitive Neuroscience, Baltimore

27157

Wake Forest University Health Services, Winston-Salem

29406

Medical University of South Carolina, North Charleston

30322

Emory University Dept. of Psychiatry, Atlanta

32224

Mayo Clinic, Jacksonville, Jacksonville

33140

Wien Center, Miami Beach

33617

University of South Florida Suncoast Alzheimer's and Gerontology Center, Tampa

33647

Byrd Alzheimer's Institute, Tampa

35294

University of Alabama, Birmingham, Birmingham

37208

Meharry Medical College, Nashville

40536

University of Kentucky, Lexington, Sanders-Brown Center on Aging/Neurology, Lexington

43210

The Ohio State University, Columbus

44120

Case Western Reserve University Memory and Aging Center, Cleveland

46202

Indiana University, Indianapolis

48105

University of Michigan Dept. of Neurology, Ann Arbor

49503

Saint Mary's Health Care, Grand Rapids

53705

University of Wisconsin Department of Medicine, Madison

55905

Mayo Clinic Rochester, Alzheimer's Disease Research Center, Rochester

60611

Northwestern University Cognitive Neurology and Alzheimer Disease Center, Chicago

60612

Rush Alzheimer's Disease Center, Chicago

63104

Saint Louis University, Department of Psychiatry, St Louis

63108

Washington University ADRC-Memory and Aging Project, St Louis

66160

University of Kansas Medical Center, Kansas City

75390

University of Texas Southwestern-Memory Research Unit, Dallas

77030

Baylor University Department of Neurology, Houston

85006

Banner Alzheimer's Institute, Phoenix

85351

Sun Health Research Institute/Arizona Consortium, Sun City

90033

University of Southern California Psychiatry and Behavioral Sciences, Los Angeles

90095

UCLA Neurology, Los Angeles

92037

UCSD Shiley-Marcos Alzheimer's Research Center, La Jolla

92103

Pacific Research Network, San Diego

92697

University of California Irvine, Irvine

94304

Palo Alto Institute for Research & Education, Palo Alto

95817

UC-Davis Alzheimer's Disease Center, Sacramento

97239

Oregon Health and Science University Neurology, Portland

98108

University of Washington/Seattle Institute for Biomedical & Clinical Research, Seattle

06510

Yale University School of Medicine, New Haven

02115

Brigham and Women's Hospital, Boston

02118

Boston University Alzheimer's Disease Clinical and Research Program, Boston

03756

Dartmouth-Hitchcock Medical Center, Lebanon

02903

Rhode Island Hospital Neurology, Providence

05201

The Memory Clinic, Bennington

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

DSM Nutritional Products, Inc.

INDUSTRY

lead

Alzheimer's Disease Cooperative Study (ADCS)

OTHER

NCT00440050 - DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease | Biotech Hunter | Biotech Hunter